Monitor upcoming in vivo pharmacokinetic and biodistribution data, which will be the next key catalyst for SIL204's systemic delivery thesis. The Phase 2/3 site initiation progress in Germany and Israel is also worth tracking for clinical execution signals.
Price Chart
Executive Summary
Silexion Therapeutics reported positive preclinical in vitro findings for its lead siRNA candidate SIL204, demonstrating that the drug utilizes native circulating lipoproteins for cellular uptake and KRAS oncogene knockdown without requiring artificial nanoparticles. The data provide mechanistic support for systemic subcutaneous delivery in the ongoing Phase 2/3 pancreatic cancer trial, but remain early-stage translational results with no new clinical data or financial figures.
Key Facts
- SIL204 showed dose-dependent gene silencing in KRAS-driven cancer cells using physiological serum lipids in a carrier-free assay.
- Depletion of serum lipids resulted in a statistically significant reduction in knockdown efficiency (P < 0.001).
- Addition of exogenous LDL did not alter potency vs. complete serum alone, indicating endogenous lipoproteins are sufficient.
- The company is actively initiating clinical trial sites (Tel Aviv Sourasky Medical Center) and obtaining regulatory clearances in Germany.
- Additional in vivo PK, cellular uptake kinetics, and biodistribution studies are ongoing.
Financial Impact
No financial figures reported; preclinical data only.
Risk Factors
- In vitro findings may not translate to in vivo efficacy or clinical outcomes.
- Company is pre-revenue and will require additional capital to complete the Phase 2/3 trial.
- Nasdaq listing maintenance risk noted in forward-looking statements.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-004628 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-004628 |
| Document: 0001178913-26-004628-index-headers.html | 0001178913-26-004628 |
| Document: 0001178913-26-004628-index.html | 0001178913-26-004628 |
| Document: 0001178913-26-004628.txt | 0001178913-26-004628 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1700 (−10.53%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1700 (+35.31%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1700 (−38.63%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1700 (+38.69%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1700 (+46.54%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1700 (+46.61%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1700 (−31.56%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1700 (−31.56%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1700 (+31.56%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1700 (+59.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers